Skip to main content
SpringerLink
Log in

Biomarker Applications in Diagnostics of Fungal Infections

  • Chapter
  • First Online:
Immunogenetics of Fungal Diseases

  • 543 Accesses

Abstract

Diagnosing invasive mold disease has long been problematic owing to the inability to culture the causal fungal agent from blood or other body fluids. This has fueled an interest in nonculture-based techniques such as the detection of galactomannan in blood and bronchoalveolar fluid, the detection of beta-D-glucan in blood, and the detection of fungal DNA by PCR-based platforms. The past decades have witnessed important improvements in our understanding of the strengths and limitations of the antigen assays and in the standardization of PCR-based DNA techniques. These assays are now being incorporated into care pathways and diagnostic algorithms; they help us to steward and monitor antifungal therapies and to predict treatment outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Herbrecht R, Bories P, Moulin JC, et al. Risk stratification for invasive aspergillosis in immunocompromised patients. Ann N Y Acad Sci. 2012;1272:23–30. doi:10.1111/j.1749-6632.2012.06829.x.

    Article  PubMed  Google Scholar 

  2. Meersseman W, Van Wijngaerden E. Invasive aspergillosis in the ICU: an emerging disease. Intensive Care Med. 2007;33(10):1679–81.

    Article  PubMed  Google Scholar 

  3. Taccone FS, Van den Abeele AM, Bulpa P, et al. Epidemiology of invasive aspergillosis in critically ill patients: clinical presentation, underlying conditions, and outcomes. Crit Care. 2015;19:7. doi:10.1186/s13054-014-0722-7.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Sinkó J, Csomor J, Nikolova R, et al. Invasive fungal disease in allogeneic hematopoietic stem cell transplant recipients: an autopsy-driven survey. Transpl Infect Dis. 2008;10(2):106–9.

    Article  PubMed  Google Scholar 

  5. Maertens J, Buvé K, Anaissie E. Broad-spectrum antifungal prophylaxis in patients with cancer at high risk for invasive mold infections: counterpoint. J Natl Compr Cancer Netw. 2008;6(2):183–9.

    Google Scholar 

  6. Maertens J, Huysmans G, Theunissen K. Early diagnosis and preemptive therapy of pulmonary mold infections in high-risk patients. Curr Infect Dis Rep. 2008;10(6):459–65.

    Article  PubMed  Google Scholar 

  7. Arendrup MC, Bille J, Dannaoui E, et al. ECIL-3 classical diagnostic procedures for the diagnosis of invasive fungal diseases in patients with leukaemia. Bone Marrow Transplant. 2012;47(8):1030–45. doi:10.1038/bmt.2011.246.

    Article  CAS  PubMed  Google Scholar 

  8. Rickerts V, Mousset S, Lambrecht E, et al. Comparison of histopathological analysis, culture, and polymerase chain reaction assays to detect invasive mold infections from biopsy specimens. Clin Infect Dis. 2007;44(8):1078–83.

    Article  PubMed  Google Scholar 

  9. Guinea J, Torres-Narbona M, Gijón P, et al. Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome. Clin Microbiol Infect. 2010;16(7):870–7. doi:10.1111/j.1469-0691.2009.03015.x.

    Article  CAS  PubMed  Google Scholar 

  10. Bouza E, Guinea J, Peláez T, et al. Workload due to Aspergillus fumigatus and significance of the organism in the microbiology laboratory of a general hospital. J Clin Microbiol. 2005;43(5):2075–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Morton CO, Loeffler J, De Luca A, et al. Dynamics of extracellular release of Aspergillus fumigatus DNA and galactomannan during growth in blood and serum. J Med Microbiol. 2010;59(4):408–13. doi:10.1099/jmm.0.017418-0.

    Article  CAS  PubMed  Google Scholar 

  12. Hope WW, Kruhlak MJ, Lyman CA, et al. Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: implications for antifungal therapy. J Infect Dis. 2007;195(3):455–66.

    Article  CAS  PubMed  Google Scholar 

  13. Barton RC. Laboratory diagnosis of invasive aspergillosis: from diagnosis to prediction of outcome. Sci (Cairo). 2013;2013:459405. doi:10.1155/2013/459405.

    Google Scholar 

  14. Miceli MH, Maertens J. Role of non-culture-based tests, with an emphasis on galactomannan testing for the diagnosis of invasive Aspergillosis. Semin Respir Crit Care Med. 2015;36(5):650–61. doi:10.1055/s-0035-1562892.

    Article  PubMed  Google Scholar 

  15. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813–21. doi:10.1086/588660.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Mennink-Kersten MA, Donnelly JP, Verweij PE. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis. 2004;4(6):349–57.

    Article  CAS  PubMed  Google Scholar 

  17. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis. 2006;42(10):1417–27.

    Article  CAS  PubMed  Google Scholar 

  18. Leeflang MM, Debets-Ossenkopp YJ, Wang J, et al. Galactomannan detection for invasive aspergillosis in immunocompromised patients. Cochrane Database Syst Rev. 2015;12:CD007394. doi:10.1002/14651858.CD007394.

    Google Scholar 

  19. Chamilos G, Luna M, Lewis RE, et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989–2003). Haematologica. 2006;91(7):986–9.

    PubMed  Google Scholar 

  20. Lewis RE, Kontoyiannis DP. Invasive aspergillosis in glucocorticoid-treated patients. Med Mycol. 2009;47(Suppl 1):S271–81. doi:10.1080/13693780802227159.

    Article  CAS  PubMed  Google Scholar 

  21. Galactomannan – Food and Drug Administration – www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm472606.pdf

  22. Marchetti O, Lamoth F, Mikulska M, et al. ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients. Bone Marrow Transplant. 2012;47(6):846–54. doi:10.1038/bmt.2011.178.

    Article  CAS  PubMed  Google Scholar 

  23. Zou M, Tang L, Zhao S, et al. Systematic review and meta-analysis of detecting galactomannan in bronchoalveolar lavage fluid for diagnosing invasive aspergillosis. PLoS ONE. 2012;7(8):e43347. doi:10.1371/journal.pone.0043347.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Guo YL, Chen YQ, Wang K, et al. Accuracy of BAL galactomannan in diagnosing invasive aspergillosis: a bivariate meta-analysis and systematic review. Chest. 2010;138(4):817–24. doi:10.1378/chest.10-0488.

    Article  PubMed  Google Scholar 

  25. D’Haese J, Theunissen K, Vermeulen E, et al. Detection of galactomannan in bronchoalveolar lavage fluid samples of patients at risk for invasive pulmonary aspergillosis: analytical and clinical validity. J Clin Microbiol. 2012;50(4):1258–63. doi:10.1128/JCM.06423-11.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Chong GM, Maertens JA, Lagrou K, et al. Diagnostic performance of galactomannan antigen testing in cerebrospinal fluid. J Clin Microbiol. 2016;54(2):428–4231. doi:10.1128/JCM.02913-15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Lamoth F, Cruciani M, Mengoli C, et al. β-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3). Clin Infect Dis. 2012;54(5):633–43. doi:10.1093/cid/cir897.

    Article  PubMed  Google Scholar 

  28. White PL, Wingard JR, Bretagne S, et al. Aspergillus polymerase chain reaction: systematic review of evidence for clinical use in comparison with antigen testing. Clin Infect Dis. 2015;61(8):1293–303. doi:10.1093/cid/civ507.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Hou TY, Wang SH, Liang SX, et al. The screening performance of serum 1,3-beta-D-glucan in patients with invasive fungal diseases: a meta-analysis of prospective cohort studies. PLoS ONE. 2015;10(7):e0131602. doi:10.1371/journal.pone.0131602.

    Article  PubMed  PubMed Central  Google Scholar 

  30. He S, Hang JP, Zhang L, et al. A systematic review and meta-analysis of diagnostic accuracy of serum 1,3-β-D-glucan for invasive fungal infection: focus on cutoff levels. J Microbiol Immunol Infect. 2015;48(4):351–61. doi:10.1016/j.jmii.2014.06.009.

    Article  CAS  PubMed  Google Scholar 

  31. Lu Y, Chen YQ, Guo YL, et al. Diagnosis of invasive fungal disease using serum (1→3)-β-D-glucan: a bivariate meta-analysis. Intern Med. 2011;50(22):2783–91.

    Article  CAS  PubMed  Google Scholar 

  32. Karageorgopoulos DE, Vouloumanou EK, Ntziora F, et al. β-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis. 2011;52(6):750–70. doi:10.1093/cid/ciq206.

    Article  CAS  PubMed  Google Scholar 

  33. Theel ES, Jespersen DJ, Iqbal S, et al. Detection of (1, 3)-β-D-glucan in bronchoalveolar lavage and serum samples collected from immunocompromised hosts. Mycopathologia. 2013;175(1–2):33–41. doi:10.1007/s11046-012-9579-y.

    Article  CAS  PubMed  Google Scholar 

  34. White PL, Wiederhold NP, Loeffler J, et al. Comparison of nonculture blood-based tests for diagnosing invasive Aspergillosis in an animal model. J Clin Microbiol. 2016;54(4):960–6. doi:10.1128/JCM.03233-15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Loeffler J, Mengoli C, Springer J, et al. Analytical comparison of in vitro-spiked human serum and plasma for PCR-based detection of Aspergillus fumigatus DNA: a study by the European Aspergillus PCR Initiative. J Clin Microbiol. 2015;53(9):2838–45. doi:10.1128/JCM.00906-15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. White PL, Barnes RA, Springer J, et al. Clinical performance of Aspergillus PCR for testing serum and plasma: a study by the European Aspergillus PCR initiative. J Clin Microbiol. 2015;53(9):2832–7. doi:10.1128/JCM.00905-15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Lyon GM, Abdul-Ali D, Loeffler J, et al. Development and evaluation of a calibrator material for nucleic acid-based assays for diagnosing aspergillosis. J Clin Microbiol. 2013;51(7):2403–5. doi:10.1128/JCM.00744-13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. White PL, Mengoli C, Bretagne S, et al. Evaluation of Aspergillus PCR protocols for testing serum specimens. J Clin Microbiol. 2011;49(11):3842–8. doi:10.1128/JCM.05316-11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. White PL, Perry MD, Loeffler J, et al. Critical stages of extracting DNA from Aspergillus fumigatus in whole-blood specimens. J Clin Microbiol. 2010;48(10):3753–5. doi:10.1128/JCM.01466-10.

    Article  PubMed  PubMed Central  Google Scholar 

  40. White PL, Bretagne S, Klingspor L, et al. Aspergillus PCR: one step closer to standardization. J Clin Microbiol. 2010;48(4):1231–40. doi:10.1128/JCM.01767-09.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Arvanitis M, Ziakas PD, Zacharioudakis IM, et al. PCR in diagnosis of invasive aspergillosis: a meta-analysis of diagnostic performance. J Clin Microbiol. 2014;52(10):3731–42. doi:10.1128/JCM.01365-14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Kourkoumpetis TK, Fuchs BB, Coleman JJ, et al. Polymerase chain reaction-based assays for the diagnosis of invasive fungal infections. Clin Infect Dis. 2012;54(9):1322–31. doi:10.1093/cid/cis132.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Mengoli C, Cruciani M, Barnes RA, et al. Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis. Lancet Infect Dis. 2009;9(2):89–96. doi:10.1016/S1473-3099(09)70019-2.

    Article  CAS  PubMed  Google Scholar 

  44. Arvanitis M, Anagnostou T, Mylonakis E. Galactomannan and polymerase chain reaction-based screening for invasive Aspergillosis among high-risk hematology patients: a diagnostic meta-analysis. Clin Infect Dis. 2015;61(8):1263–72. doi:10.1093/cid/civ555.

    Article  CAS  PubMed  Google Scholar 

  45. Heng SC, Morrissey O, Chen SC, et al. Utility of bronchoalveolar lavage fluid galactomannan alone or in combination with PCR for the diagnosis of invasive aspergillosis in adult hematology patients: a systematic review and meta-analysis. Crit Rev Microbiol. 2015;41(1):124–34. doi:10.3109/1040841X.2013.804033.

    Article  CAS  PubMed  Google Scholar 

  46. Thornton C, Johnson G, Agrawal S. Detection of invasive pulmonary aspergillosis in haematological malignancy patients by using lateral-flow technology. J Vis Exp. 2012;(61). pii: 3721. doi:10.3791/3721.

  47. Thornton CR. Development of an immunochromatographic lateral-flow device for rapid serodiagnosis of invasive aspergillosis. Clin Vaccine Immunol. 15(7):1095–105. doi:10.1128/CVI.00068-08.

  48. Pan Z, Fu M, Zhang J, et al. Diagnostic accuracy of a novel lateral-flow device in invasive aspergillosis: a meta-analysis. J Med Microbiol. 2015;64(7):702–7. doi:10.1099/jmm.0.000092.

    Article  CAS  PubMed  Google Scholar 

  49. Eigl S, Prattes J, Reinwald M, et al. Influence of mould-active antifungal treatment on the performance of the Aspergillus-specific bronchoalveolar lavage fluid lateral-flow device test. Int J Antimicrob Agents. 2015;46(4):401–5. doi:10.1016/j.ijantimicag.2015.05.017.

    Article  CAS  PubMed  Google Scholar 

  50. de Heer K, van der Schee MP, Zwinderman K, et al. Electronic nose technology for detection of invasive pulmonary aspergillosis in prolonged chemotherapy-induced neutropenia: a proof-of-principle study. J Clin Microbiol. 2013;51(5):1490–5. doi:10.1128/JCM.02838-12.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Koo S, Thomas HR, Daniels SD, et al. A breath fungal secondary metabolite signature to diagnose invasive aspergillosis. Clin Infect Dis. 2014;59(12):1733–4170. doi:10.1093/cid/ciu725.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Domingo MP, Colmenarejo C, Martínez-Lostao L, et al. Bis(methyl)gliotoxin proves to be a more stable and reliable marker for invasive aspergillosis than gliotoxin and suitable for use in diagnosis. Diagn Microbiol Infect Dis. 2012;73(1):57–64. doi:10.1016/ j.diagmicrobio.2012.01.012.

    Article  CAS  PubMed  Google Scholar 

  53. Vidal-García M, Domingo MP, De Rueda B, et al. Clinical validity of bis(methylthio)gliotoxin for the diagnosis of invasive aspergillosis. Appl Microbiol Biotechnol. 2016;100(5):2327–34. doi:10.1007/s00253-015-7209-6.

    Article  PubMed  Google Scholar 

  54. Nucci M, Anaissie E. How we treat invasive fungal diseases in patients with acute leukemia: the importance of an individualized approach. Blood. 2014;124(26):3858–6389. doi:10.1182/blood-2014-04-516211.

    Article  CAS  PubMed  Google Scholar 

  55. Donnelly JP, Leeflang MM. Galactomannan detection and diagnosis of invasive aspergillosis. Clin Infect Dis. 2010;50(7):1070–1. author reply 1071–2 doi:10.1086/651161.

    Article  PubMed  Google Scholar 

  56. Marr KA, Balajee SA, McLaughlin L, et al. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis. 2004;190(3):641–9.

    Article  CAS  PubMed  Google Scholar 

  57. Marr KA, Laverdiere M, Gugel A, et al. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis. 2005;40(12):1762–9.

    Article  CAS  PubMed  Google Scholar 

  58. Duarte RF, Sánchez-Ortega I, Cuesta I, et al. Serum galactomannan-based early detection of invasive aspergillosis in hematology patients receiving effective antimold prophylaxis. Clin Infect Dis. 2014;59(12):1696–702. doi:10.1093/cid/ciu673.

    Article  PubMed  Google Scholar 

  59. Maschmeyer G, Donnelly JP. How to manage lung infiltrates in adults suffering from haematological malignancies outside allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2016;173(2):179–819. doi:10.1111/bjh.13934.

    Article  CAS  PubMed  Google Scholar 

  60. Nucci M, Nouér SA, Cappone D, et al. Early diagnosis of invasive pulmonary aspergillosis in hematologic patients: an opportunity to improve the outcome. Haematologica. 2013;98(11):1657–60. doi:10.3324/haematol.2013.094359.

    Article  PubMed  PubMed Central  Google Scholar 

  61. De Pauw BE, Donnelly JP. Prophylaxis and aspergillosis – has the principle been proven? N Engl J Med. 2007;356(4):409–11.

    Article  CAS  PubMed  Google Scholar 

  62. Aguilar-Guisado M, Martín-Peña A, Espigado I, et al. Universal antifungal therapy is not needed in persistent febrile neutropenia: a tailored diagnostic and therapeutic approach. Haematologica. 2012;97(3):464–71. doi:10.3324/haematol.2011.049999.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Barnes RA, White PL, Bygrave C, et al. Clinical impact of enhanced diagnosis of invasive fungal disease in high-risk haematology and stem cell transplant patients. J Clin Pathol. 2009;62(1):64–9. doi:10.1136/jcp.2008.058354.

    Article  CAS  PubMed  Google Scholar 

  64. Barnes RA, Stocking K, Bowden S, et al. Prevention and diagnosis of invasive fungal disease in high-risk patients within an integrative care pathway. J Infect. 2013;67(3):206–14. doi:10.1016/j.jinf.2013.04.020.

    Article  PubMed  Google Scholar 

  65. Aguado JM, Vázquez L, Fernández-Ruiz M, et al. Serum galactomannan versus a combination of galactomannan and polymerase chain reaction-based Aspergillus DNA detection for early therapy of invasive aspergillosis in high-risk hematological patients: a randomized controlled trial. Clin Infect Dis. 2015;60(3):405–14. doi:10.1093/cid/ciu833.

    Article  CAS  PubMed  Google Scholar 

  66. Morrissey CO, Chen SC, Sorrell TC, et al. Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomized controlled trial. Lancet Infect Dis. 2013;13(6):519–28. doi:10.1016/S1473-3099(13)70076-8.

    Article  CAS  PubMed  Google Scholar 

  67. Fisher CE, Michal Stevens A, Leisenring W, et al. The serum galactomannan index predicts mortality in hematopoietic stem cell transplant recipients with invasive Aspergillosis. Clin Infect Dis. 2013;57(7):1001–4. doi:10.1093/cid/cit393.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Maertens J, Buvé K, Theunissen K, et al. Galactomannan serves as a surrogate endpoint for outcome of pulmonary invasive aspergillosis in neutropenic hematology patients. Cancer. 2009;115(2):355–62. doi:10.1002/cncr.24022.

    Article  PubMed  Google Scholar 

  69. Chai LYA, Kullberg BJ, Johnson EM, et al. Early serum galactomannan trend as a predictor of outcome of invasive Aspergillosis. J Clin Microbiol. 2012;50(7):2330–6. doi:10.1128/JCM.06513-11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Koo S, Bryar JM, Baden LR, et al. Prognostic features of galactomannan antigenemia in galactomannan-positive invasive Aspergillosis. J Clin Microbiol. 2010;48(4):1255–60. doi:10.1128/JCM.02281-09.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Neofytos D, Railkar R, Mullane KM, et al. Correlation between circulating fungal biomarkers and clinical outcome in invasive Aspergillosis. PLoS ONE. 2015;10(6):e0129022. doi:10.1371/journal.pone.0129022.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Marr KA, Schlamm HT, Herbrecht R, et al. Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med. 2015;162(2):81–9. doi:10.7326/M13-2508.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium

    Johan Maertens

  2. Department of Microbiology and Immunology, KU Leuven – University of Leuven, Leuven, Belgium

    Katrien Lagrou

  3. Department of Laboratory Medicine and National Reference Center for Medical Mycology, University Hospitals Leuven, Leuven, Belgium

    Katrien Lagrou

Authors
  1. Johan Maertens
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Katrien Lagrou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Johan Maertens .

Editor information

Editors and Affiliations

  1. Life and Health Sciences Research Institute (ICVS), University of Minho, School of Medicine, Braga, Portugal

    Agostinho Carvalho

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Maertens, J., Lagrou, K. (2017). Biomarker Applications in Diagnostics of Fungal Infections. In: Carvalho, A. (eds) Immunogenetics of Fungal Diseases. Springer, Cham. https://doi.org/10.1007/978-3-319-50842-9_8

Download citation

Publish with us

Policies and ethics

Search

Navigation